Bio-Path (BPTH) Upgraded by ValuEngine to Sell

ValuEngine upgraded shares of Bio-Path (NASDAQ:BPTH) from a strong sell rating to a sell rating in a research note released on Friday.

Several other analysts have also recently commented on BPTH. HC Wainwright reissued a buy rating and set a $1.50 price target (down from $4.50) on shares of Bio-Path in a research note on Monday, November 13th. decreased their price target on shares of Bio-Path from $4.50 to $1.50 and set a buy rating on the stock in a research note on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $1.67.

Shares of Bio-Path (BPTH) opened at $0.19 on Friday. Bio-Path has a 52 week low of $0.17 and a 52 week high of $1.01. The company has a market cap of $19.88, a P/E ratio of -2.70 and a beta of 3.01.

Bio-Path (NASDAQ:BPTH) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.02) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.02). equities analysts anticipate that Bio-Path will post -0.08 EPS for the current fiscal year.

An institutional investor recently raised its position in Bio-Path stock. Sabby Management LLC boosted its holdings in Bio-Path Holdings Inc (NASDAQ:BPTH) by 73.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,190,886 shares of the company’s stock after buying an additional 503,488 shares during the period. Sabby Management LLC owned approximately 1.19% of Bio-Path worth $462,000 as of its most recent SEC filing. 9.31% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Bio-Path (BPTH) Upgraded by ValuEngine to Sell” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at

Bio-Path Company Profile

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with's FREE daily email newsletter.

Leave a Reply